Detected ·
Kernal Biologics
—Other
Kernal Biologics (Kernal Bio) announced a new strategic investment from the Institute for Follicular Lymphoma Innovation (IFLI) to advance its mRNA-encoded in vivo CAR-T candidate KR-402.
- Website
- —
- linkedin.com/company/15196047
- Amount
- —
- Stage
- Other
- Event
- Funding round
- Detected
- 2026-11-19 04:12:33 UTC
- Signal ID
- 0074a3fa-1174-4ef4-b118-4d4ade3afc77
As the API returns it
{
"id": "0074a3fa-1174-4ef4-b118-4d4ade3afc77",
"created_at": "2026-11-19T04:12:33.465427Z",
"company_name": "Kernal Biologics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/15196047",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": "other",
"message": "*Kernal Biologics (Kernal Bio) announced a new strategic investment from the Institute for Follicular Lymphoma Innovation (IFLI) to advance its mRNA-encoded in vivo CAR-T candidate KR-402.*"
}